MORE►
Brian J. Brille
David Halbert, founder, chairman, and CEO of Caris Life Sciences. [Courtesy: Caris]
Irving’s Caris Life Sciences Files for IPO, Backed by AI-Driven Precision Oncology Platform
by Lance Murray | May 28, 2025
With $1.86 billion raised since 2018 and recent product launches, the North Texas life science company founded in 2008 is preparing for a public debut on the Nasdaq Global Select Market, following a $168 million growth capital round in April.
by Lance Murray |
Jan 23, 2023
Caris Life Sciences, the Irving-based biotech company, announced Thursday that it closed a senior secured term loan providing up to $400 million in capital from OrbiMed and Braidwell, bringing its funding total since 2018 to roughly $1.7 billion....
MORE►
by Alex Edwards |
Oct 27, 2020
The growth capital will allow Caris to advance its position as a leading tumor profiling company that aims to reinvent cancer care.
MORE►
